Viemed Healthcare, Inc. (NASDAQ:VMD) Stock Has Average Target Price of $12.00

Shares of Viemed Healthcare, Inc. (NASDAQ:VMD) have been assigned a consensus rating of “Hold” from the five ratings firms that are presently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $12.00.

VMD has been the topic of several research reports. Weiss Ratings cut Viemed Healthcare from a “buy (b-)” rating to a “hold (c+)” rating in a report on Monday, August 17th. Barrington Research initiated coverage on Viemed Healthcare in a research note on Monday, August 24th. They set an “outperform” rating and a $14.00 price objective for the company. Freedom Broker reduced their price objective on Viemed Healthcare from $11.00 to $10.00 and set a “hold” rating for the company in a research note on Monday. Freedom Capital cut Viemed Healthcare from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 5th. Finally, Wall Street Zen raised Viemed Healthcare from a “buy” rating to a “strong-buy” rating in a research report on Saturday.

Viemed Healthcare Price Performance

Shares of NASDAQ:VMD traded down $0.20 during trading hours on Monday, hitting $8.93. 285,977 shares of the company’s stock traded hands, compared to its average volume of 284,811. The company’s fifty day simple moving average is $9.26 and its two-hundred day simple moving average is $9.59. The company has a market cap of $338.38 million, a price-to-earnings ratio of 23.50, a price-to-earnings-growth ratio of 2.21 and a beta of 1.05. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.16 and a current ratio of 1.25. Viemed Healthcare has a 52 week low of $6.18 and a 52 week high of $12.61.

Viemed Healthcare (NASDAQ:VMD) last released its earnings results on Wednesday, November 4th. The company reported $0.11 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.01). The business had revenue of $80.67 million for the quarter, compared to analyst estimates of $80.78 million. Viemed Healthcare had a net margin of 5.03% and a return on equity of 10.64%. As a group, equities analysts anticipate that Viemed Healthcare will post 0.41 EPS for the current fiscal year.

Institutional Trading of Viemed Healthcare

Several institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. purchased a new position in shares of Viemed Healthcare in the second quarter worth approximately $54,587,000. Nantahala Capital Management LLC purchased a new stake in shares of Viemed Healthcare in the second quarter valued at $7,209,873. Arrowstreet Capital Limited Partnership boosted its position in shares of Viemed Healthcare by 101.9% in the first quarter. Arrowstreet Capital Limited Partnership now owns 711,186 shares of the company’s stock worth $6,550,000 after buying an additional 358,863 shares during the period. Punch & Associates Investment Management Inc. acquired a new stake in shares of Viemed Healthcare in the second quarter worth $6,082,000. Finally, Raffles Associates LP purchased a new position in shares of Viemed Healthcare during the second quarter valued at $4,602,000. Institutional investors and hedge funds own 74.24% of the company’s stock.

About Viemed Healthcare

Viemed Healthcare, Inc (NASDAQ: VMD) is a U.S. healthcare company that provides in-home medical equipment and clinical services for patients with chronic respiratory and other complex medical conditions. Its services are designed to help patients receive care at home while supporting hospitals and clinicians in managing ongoing conditions.

The company’s offerings include non-invasive ventilation, oxygen therapy, sleep-apnea equipment, respiratory therapy, remote patient monitoring and related durable medical equipment.